

25th November 2025

Close* – ₹1,153/-

View – Hold

Q2FY26 Performance

- The company delivered a strong performance in Q2FY26, with Network net revenue increasing to ₹2,580crs, reflecting +21% YoY and +5% QoQ growth, led by a significant rise in Occupied Bed Days (OBDs). International patient revenue remained robust at ₹231crs, growing +25% YoY and +11% QoQ, and contributed ~9% to overall hospital revenues.
- Network Operating EBITDA was ₹694crs, up +23% YoY, with an EBITDA margin of 26.9%. Reported PAT was ₹554crs, compared to ₹349crs in Q2FY25 and ₹345crs in Q1FY26, a growth of +59% YoY; this includes a favourable one-time tax gain of ~₹149crs from the merger of two wholly owned subsidiaries—Crosslay Remedies Limited (CRL) and Jaypee Healthcare Limited (JHL). Excluding this exceptional item, underlying PAT stood at ₹406crs, a YoY increase of +16%.
- EBITDA per bed improved to ₹73.4 lakhs (₹76.5 lakhs for existing units). Occupancy remained strong at 77% with OBDs up +19% YoY, and ARPOB stood at ₹77.3k.
- During the quarter, the network provided free treatment to 42,522 OPD patients and 1,547 IPD patients from economically weaker sections.
- In the asset-light verticals, Max Lab reported revenue of ₹54crs (+16% YoY, +11% QoQ) across 60+ cities offering 2,700+ tests, while Max@Home delivered ₹63crs (+20% YoY, +6% QoQ), driven by physiotherapy & rehab, critical care assistance, medicine delivery, and medical room services.

Concall Highlights

○ Occupancy, ARPOB and Per-Bed Metrics

- Network occupancy remained steady at 77% (79% for existing units), supported by healthy throughput and increased patient volumes across specialties.
- ARPOB stood at ₹77.3k, broadly stable YoY and QoQ at the network level due to dilution from newer hospitals. On a like-for-like basis, existing units recorded ~7% ARPOB growth.
- EBITDA per bed improved to ₹73.4 lakhs for the network and ₹76.5 lakhs for existing units, reflecting better operating leverage and improved case mix. ARPOB growth appeared at 3%yoy, but management clarified that the adjusted like-for-like ARPOB was +6–7% YoY.
- Network ARPOB looks lower due to: Newly acquired or started units (Nagpur, Noida, Dwarka), Lower ARPOB plus higher contribution of these units in the mix and No structural slowdown in pricing or case mix.

○ Capacity Expansion and Project Updates

- The company highlighted significant progress on brownfield expansion, adding ~830 new beds across metros.
- **Mohali:** 160-bed tower commissioned along with a new radiation oncology program. Commissioning is floor-wise—only completed floors are operational, with the remainder to be ramped up in Q3.
- **Nanavati:** 268-bed tower expected to be commissioned within a week.
- **Max Smart Saket:** 400-bed tower expected to be commissioned in about 30 days.

Important Statistics

Nifty	25,959
Sensex	85,231
Close*(₹)	1,153
M.CAP (₹ tn)	₹1.12
52 Week H/L (₹)	₹1,314/940
NSE Code	MAXHEALTH
BSE Code	543220
Bloomberg Code	MAXHEALT:IN

Close* as on 24th Nov 2025

Shareholding pattern (%) Sep'25

Promoter	23.74
FII	54.76
DII	17.42
Public & Others	4.08

Financials

Particulars	FY23	FY24	FY25	FY26E	FY27E
Revenues	5,904	6,849	8,667	10,908	11,568
EBITDA	1,598	1,840	2,240	2,727	3,065
EBITDA Margin (%)	27%	27%	26%	25%	27%
Net Profit	1,085	1,278	1,335	1,676	1,848
Net Profit margin %	18%	19%	15%	15%	16%
EPS (₹)	11	13	14	17	19
RoE (%)	13%	14%	9%	13%	13%
RoCE (%)	14%	14%	10%	14%	13%
P/E (x)	104	88	110	67	61
EV/EBITDA (x)	68	59	58	41	36

Source: Company, Way2Wealth Research

Relative Performance

Returns (%)	1 Yr	3Yr	5 Yr
MAXHEALTH	20%	168%	814%
Sensex	6%	36%	94%
Nifty	7%	40%	102%

Rupali Singh

rupalisingh@way2wealth.com
91-22-4019 2907


25th November 2025

Close* – ₹1,153/-

View – **Hold**

- Additional expansion projects across Lucknow, Gurgaon Sector-56, Vaishali, Thane, and Zirakpur continue to move forward.
- Management reiterated that brownfield projects typically achieve near-immediate EBITDA breakeven, offering strong ROCE potential.
- **CGHS Tariff Revision and Insurance Update**
 - Management confirmed implementation of the long-awaited CGHS tariff revision effective 13 October.
 - Once fully operational, this revision is expected to add over ₹200crs in annual revenue with 85–90% EBITDA flow-through.
 - Coding for super-specialty hospital categories is pending and expected within 15–20 days. The full financial impact will begin reflecting from FY27 onward.
 - Regarding insurance, the temporary impasse with select insurers has been resolved, with no volume impact as patients shifted to cash-pay during the disruption. Discussions with GIPSA and other insurers are ongoing.
- **Performance of Noida and Dwarka Units**
 - The Noida facility showed consistent improvement, with an EBITDA margin of ~18%, expected to gradually progress toward the mid-20s as occupancy and case mix mature.
 - Dwarka operated at ~81% occupancy with a margin of ~15%, impacted by a higher institutional patient mix.
 - ARPOB is expected to improve once the oncology bunker becomes operational.
 - Dwarka currently has 285 operational beds out of 300, and given strong demand, the company is evaluating a 200-bed brownfield expansion at this site.
- **PAT Growth Lower Than EBITDA Growth**
 - Finance costs increased due to the addition of new hospitals (particularly the JP acquisition last year).
 - Newer hospitals have lower EBITDA initially, resulting in overall margin dilution.
 - Management noted that as these hospitals mature and scale up, PAT growth will normalize and move closer to EBITDA growth trends.

Valuation & Outlook

- Max Healthcare has outlined an ambitious expansion roadmap to add over 7,000 beds, with approximately 3,700 beds expected to be commissioned over the next four years. This expansion will be executed through a mix of brownfield, greenfield, and asset-light projects. In FY24 and FY25, the company added around 3,500 and 1,393 beds, respectively, through a combination of inorganic acquisitions and greenfield developments.
- Looking ahead, Max Healthcare plans to add 1,464 beds in FY26, 299 beds in FY27, and 2,118 beds in FY28. Beyond FY28, there is potential to add another 4,050 beds, subject to finalization of specific plans. The capital outlay for this expansion is projected at ₹2,202crs in FY26, ₹1,854crs in FY27, and ₹915crs in FY28, with additional investments to be determined for the post-FY28 phase.

25th November 2025

Close* – ₹1,153/-

View – **Hold**

- Key projects under this expansion include facilities in Delhi (Max Smart), Gurugram (Sector 53), Mohali, Lucknow, Thane, Nagpur, and Dwarka. The company is also strategically leveraging its existing land bank to support future capacity additions, underscoring strong long-term growth visibility.
- We expect margins to gradually improve as the company executes a balanced expansion strategy across both brownfield and greenfield projects. For FY25–27E, we project Revenue/EBITDA/PAT to deliver a CAGR of 16%/17%/18%, supported by rising EBITDA per operational bed, while overall margins are likely to remain stable around ~27%. At the current market price, the stock trades at 61x FY27E EPS of ₹19 and 36x EV/EBITDA.
- Backed by steady earnings momentum, a diversified and scalable growth pipeline, and a robust balance sheet, **we continue to maintain our Hold rating on Max Healthcare, in line with the 30% upside potential highlighted in our initiating coverage report.**

Consolidated Quarterly performance

Particulars	(₹ crs)							
	Q2FY26	Q2FY25	YoY %	Q1FY26	QoQ %	1HFY26	1HFY25	YoY %
Net revenue	2580	2,125	21%	2460	5%	5,040	4,060	24%
Direct costs	1060	843	26%	1015	4%	2,075	1,616	28%
% of sales	41%	40%	4%	41%	0%	41%	40%	3%
Gross profit	1,520	1,282	19%	1,445	5%	2,965	2,444	21%
gross profit margins %	59%	60%	-2%	59%	0%	59%	60%	-2%
Indirect overheads	826	716	15%	831	-1%	1,657	1,379	20%
% of sales	32%	34%	-5%	34%	-5%	33%	34%	-3%
Operating EBITDA	694	566	23%	613	13%	1,307	1,065	23%
Operating EBITDA margins %	27%	27%	1%	25%	8%	26%	26%	-1%
Reported EBITDA	676	546	24%	591	14%	1,267	1,026	23%
EBITDA margins %	26%	26%		24%		25%	25%	-1%
Finance cost/(income)	41	5	720%	34	21%	75	13	477%
Depreciation and amortisation	122	97	26%	117	4%	239	187	28%
Profit before tax	513	444	16%	440	17%	953	826	15%
Profit before tax after exceptional item	513	444	16%	440	17%	953	826	15%
Tax	-41	95	-143%	96	-143%	55	182	-70%
Tax %	-8%	21%	-137%	22%	-137%	6%	22%	-74%
Profit after tax	554	349	59%	344	61%	898	644	39%
Net Profit margins %	21%	16%		14%		18%	16%	
EPS - Reported	5.70	3.59	59%	3.54	61%	9	7	39%

25th November 2025

Close* – ₹1,153/-

View – **Hold**

Financial Performance

(₹ crs)

Particulars	FY22	FY23	FY24	FY25	FY26E	FY27E
Net revenue	5,218	5,904	6,849	8,667	10908	11568
Direct costs	2,103	2,304	2,675	3,416	4,527	4,627
% of sales	40%	39%	39%	39%	42%	40%
Gross profit	3,115	3,600	4,174	5,251	6,381	6,941
gross profit margins %	60%	61%	61%	61%	59%	60%
Indirect overheads	1,725	1,964	2,267	2,932	3654	3875
% of sales	33%	33%	33%	34%	34%	34%
Reported EBITDA	1,340	1,598	1,840	2,240	2,727	3,065
EBITDA margins %	26%	27%	27%	26%	25%	27%
Finance cost/(income)	112	39	-38	84	97.5	97.5
Depreciation and amortisation	248	260	284	407	509	629
Profit before tax	980	1,299	1,594	1,749	2,121	2,339
Exceptional				-74		
Profit before tax after exceptional item	980	1,299	1,594	1,675	2,121	2,339
Tax	143	214	316	340	445	491
Profit after tax	837	1,085	1,278	1,335	1,676	1,848
Net Profit margins %	16%	18%	19%	15%	15%	16%
EPS - Reported	8.6	11.2	13.1	13.7	17.2	19.0

Source: Company, Way2wealth Research

25th November 2025

Close* – ₹1,153/-

View – Hold

Disclaimer

Analyst Certification: I, Rupali Singh the research analyst and author of this report, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s), principally responsible for the preparation of this research report, receives compensation based on overall revenues of the company (Way2Wealth Brokers Private Limited, hereinafter referred to as Way2Wealth) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

It is confirmed that Rupali Singh, the author of this report has not received any compensation from the companies mentioned in the report in the preceding 12 months. Our research professionals are paid in part based on the profitability of Way2Wealth, which include earnings from other business. Neither Way2Wealth nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information contained in this report.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Way2Wealth is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. The contents of this material are general and are neither comprehensive nor appropriate for every individual and are solely for the informational purposes of the readers. This material does not take into account the specific objectives, financial situation or needs of an individual/s or a Corporate/s or any entity/s.

This research has been prepared for the general use of the clients of the Way2Wealth and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient, you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Way2Wealth will not treat recipients as customers by virtue of their receiving this report. The distribution of this document in other jurisdictions may be restricted by the law applicable in the relevant jurisdictions and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The report is based upon information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up to date and it should not be relied upon as such. Way2Wealth or any of its affiliates or employees makes no warranties, either express or implied of any kind regarding any matter pertaining to this report, including, but not limited to warranties of suitability, fitness for a particular purpose, accuracy, timeliness, completeness or non-infringement. We accept no obligation to correct or update the information or opinions in it. Way2Wealth or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. The recipients of this report should rely on their own investigations. In no event shall Way2Wealth be liable for any damages of any kind, including, but not limited to, indirect, special, incidental, consequential, punitive, lost profits, or lost opportunity, whether or not Way2Wealth has advised of the possibility of such damages.

This material contains statements that are forward-looking; such statements are based upon the current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These uncertainties include but are not limited to: the risk of adverse movements or volatility in the securities markets or in interest or foreign exchange rates or indices; adverse impact from an economic slowdown; downturn in domestic or foreign securities and trading conditions or markets; increased competition; unfavorable political and diplomatic developments; change in the governmental or regulatory policies; failure of a corporate event and such others. This is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. No part of this material may be copied or duplicated in any form by any means or redistributed without the written consent of Way2Wealth. In no event shall any reader publish, retransmit, redistribute or otherwise reproduce any information provided by Way2Wealth in any format to anyone. Way2Wealth and its affiliates, officers, directors and employees including persons involved in the preparation or issuance of this report may from time to time have interest in securities / positions, financial or otherwise in the securities related to the information contained in this report.

To enhance transparency, Way2Wealth has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Disclosure of Interest Statement Max Healthcare Institute Ltd. as on 25th Nov 2025

Name of the Security	Max Healthcare Institute Ltd.
Name of the analyst	Rupali Singh
Analysts' ownership of any stock related to the information contained	NIL
Financial Interest	
Analyst :	No
Analyst's Relative : Yes / No	No
Analyst's Associate/Firm : Yes/No	No
Conflict of Interest	No
Receipt of Compensation	No
Way2Wealth ownership of any stock related to the information contained	NIL
Broking relationship with company covered	NIL
Investment Banking relationship with company covered	NIL

This information is subject to change without any prior notice. Way2Wealth reserves at its absolute discretion the right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, Way2Wealth is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and Enlistment with RAASB/BSE and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.